Samsung Biologics Co., Ltd. (KRX:207940) told the market on 20 July that it would pay for PolyPeptide Group AG out of cash on hand and borrowings. On 28 August it filed an amendment saying the money would come from a rights offering instead, and on the same day the board approved one: 2,270,000 new shares, ₩3,000.9bn, with ₩2,706.2bn of the proceeds earmarked for the acquisition and ₩294.8bn for facilities.
Five weeks. That is a short interval for a company of this quality to change its mind about ₩2.7tn of funding, and the change is more interesting than the amount.
Start with what Samsung Biologics did not do. It did not place shares with a third party at a negotiated price, which is the route Korean companies take when they want the money without asking existing holders. It went with allotment to existing shareholders first, with anything they decline offered to the public.
Existing holders receive 0.0392737657 new shares for each share held, based on a record date of 6 October. They can subscribe for up to 20% more than their entitlement if others pass. The employee stock ownership association gets first call on 454,000 shares, the statutory 20%. And critically, the subscription rights themselves are issued electronically, transferable, and will be listed on the exchange for at least five trading days. A holder who does not want to put up more money can sell the right rather than watch it expire worthless.
Pricing follows the conventional Korean ladder with a 15% discount at each step. An indicative price of ₩1,322,000 was set off the 27 August reference. A first price gets struck three trading days before the 6 October record date, a second three days before the 9 November subscription opens, and the final price is the lower of the two, floored at 60% of a short-window average. Payment lands 17 November, the new shares list 30 November, and the acquisition is scheduled to settle the same day.
Work backwards through the discount formula the filing sets out and the reference price implied by ₩1,322,000 comes to roughly ₩1.57m per share. On 46.3m shares that is about ₩72.5tn of market value. Against trailing four-quarter net income near ₩1,984.4bn and equity of ₩8,361.9bn, the shares are somewhere around the mid-30s on earnings and high single digits on book. Expensive by any conventional measure, and the company is issuing into it, which is at least the right direction.
It would be easy to read a ₩3tn equity raise as a sign of strain. The operating numbers say otherwise. FY2025 operating cash flow was ₩2,247.8bn. The first half of 2026 produced ₩1,392.5bn on a cumulative basis — Korean interim cash flow statements run year-to-date rather than by discrete quarter — which annualizes close to the prior year. Operating margin ran 44.4% in the second quarter. This is not a company that struggles to generate money.
What it does not do is hold money. Cash and equivalents were ₩288.6bn at the end of June, ₩148.9bn at the end of FY2025 and ₩391.2bn at the end of FY2024. Samsung Biologics converts cash into bioreactors at close to the rate it earns it. Purchases of property, plant and equipment were ₩1,391.7bn in FY2025 and ₩1,303.6bn in FY2024, and property, plant and equipment now stands at ₩6,468.0bn — 51% of total assets.
So the constraint is timing, not solvency. A Swiss-franc-denominated tender settling on a fixed date in November cannot be funded out of cash flow that arrives across 2027, and the company was not going to stop building to pay for it.
That is the question the amendment raises and does not answer.
The balance sheet has room. Total liabilities were ₩4,290.7bn at the end of June against ₩8,361.9bn of equity, a ratio of 0.51. Non-current liabilities are only ₩1,324.6bn. Before the Bioepis spin-off, at the end of FY2024, liabilities were ₩6,431.6bn against ₩10,904.7bn of equity — a slightly higher ratio than today. A company throwing off more than ₩2tn of operating cash a year, with a 44% operating margin and Samsung Group behind it, could raise ₩2.7tn of debt without anyone blinking.
Several explanations are plausible and I can't distinguish between them from the filings. The rate environment turned: the Bank of Korea took its base rate to 3.00% on 27 August, the day before the board met, in a second consecutive hike. Cross-currency funding for a Swiss franc payment adds hedging cost on top. There may be a rating consideration, or a group-level preference for keeping leverage capacity for Plant 6 and the Rockville expansion, both of which the company has said it is working on.
There is also a less comfortable reading. Equity issued at more than 30 times earnings is cheap capital if you believe the multiple, and expensive-looking stock is the classic currency for an acquisition an issuer is not certain about. I don't think that is what is happening here — the ₩294.8bn facility slice suggests genuine capital need — but a board that switched from debt to equity in five weeks should explain the switch, and the securities registration statement is where that explanation belongs.
One detail deserves flagging for anyone modelling this as a normal rights issue. Samsung Biologics' consolidated cash flow statements carry no dividends-paid line in any of the eight fiscal years on file. This is a company that has retained everything it has ever earned — retained earnings reached ₩7,770.9bn by the end of June, against share capital of ₩115.7bn.
That is a defensible policy for a business compounding capacity at these returns. It also means the ₩3tn is being asked of a shareholder base that has never received a cash return, to fund an acquisition of a company that lost money in each of the last three years. The rights are tradeable, so nobody is trapped. But the ask is real, and the 4.9% dilution understates it for anyone who chooses not to participate.
Take the other side. Equity is the correct instrument for an acquisition whose cash flows are uncertain. PolyPeptide has negative earnings and a heavy fixed-cost base, and layering fixed interest expense on top of an asset that does not yet cover its own costs is exactly how acquirers get into trouble. Funding an uncertain asset with permanent capital rather than debt is textbook conservatism, not weakness.
The structure supports that reading. A discounted rights issue with listed, transferable rights and a 20% excess subscription allowance is the version that treats existing holders best. If management were opportunistically printing stock, a third-party placement would have been faster and quieter.
And 4.9% is genuinely small. Most Korean rights offerings of this scale run to double-digit dilution.
The final issue price on 4 November. Between now and then the shares trade with a known 2.27m-share supply overhang and a short-selling prohibition running from 31 August to 4 November. If the final price lands near the ₩1,322,000 indicative figure, the market absorbed the raise without repricing the company. A final price meaningfully below it means the offering itself moved the stock, and the 15% discount was not enough.
The second thing is the take-up. Watch how many shares end up in the 12-13 November public offering of forfeited stock. A large residual means existing shareholders declined, and underwriters — Shinhan, NH, Korea Investment and KB — end up holding paper they will want to sell.
kstock reads DART every morning and writes up what moved — the contract, the buyback, the number that does not add up. The daily post and a Saturday roundup, by email.